We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+2.88%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$51M
AUM Growth
-$64.6M
Cap. Flow
-$66.3M
Cap. Flow %
-130.04%
Top 10 Hldgs %
55.64%
Holding
66
New
2
Increased
14
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$3.42M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$827K
3
KYNB
Kyntra Bio
KYNB
+$730K
4
ALXN
Alexion Pharmaceuticals
ALXN
+$513K
5
TSRO
TESARO, Inc.
TSRO
+$418K

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$5.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$5.51M
3
MRK icon
Merck
MRK
+$4.71M
4
RXDX
Ignyta, Inc.
RXDX
+$4.55M
5
AZN icon
AstraZeneca
AZN
+$4.16M

Sector Composition

Rank Sector Weight
1 Healthcare 64.08%
2 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIB icon
1
ProShares Ultra NASDAQ Biotechnology
BIB
$82.9M
$10.3M 20.26%
187,610
+57,110
+44% +$3.42M
BIB icon
2
PUT
ProShares Ultra NASDAQ Biotechnology
BIB
$82.9M
$3.3M 6.48%
+60,000
New +$3.59M
NKTR icon
3
Nektar Therapeutics
NKTR
$2.39B
$2.49M 4.88%
1,562
-4,576
-75% -$5.9M
XBI icon
4
State Street SPDR S&P Biotech ETF
XBI
$10B
$2.09M 4.1%
23,800
-41,200
-63% -$3.76M
MTD icon
5
Mettler-Toledo International
MTD
$28.1B
$2.07M 4.05%
3,594
– –
IBB icon
6
iShares Biotechnology ETF
IBB
$9.45B
$2M 3.92%
18,750
-18,750
-50% -$2.08M
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$38.3B
$1.63M 3.2%
13,680
-29,384
-68% -$3.79M
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$1.54M 3.03%
13,853
+4,295
+45% +$513K
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$123B
$1.5M 2.95%
9,224
-7,415
-45% -$1.21M
ALKS icon
10
Alkermes
ALKS
$8.11B
$1.41M 2.77%
24,333
-19,430
-44% -$1.14M
AGIO icon
11
Agios Pharmaceuticals
AGIO
$2.08B
$1.31M 2.57%
16,002
-12,702
-44% -$982K
ILMN icon
12
Illumina
ILMN
$29.5B
$1.3M 2.55%
5,660
-4,329
-43% -$992K
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
$1.11M 2.17%
21,126
-14,542
-41% -$792K
QGEN icon
14
Qiagen
QGEN
$8.62B
$1.07M 2.1%
31,276
-21,955
-41% -$771K
IONS icon
15
Ionis Pharmaceuticals
IONS
$8.93B
$1.02M 2%
23,133
-16,255
-41% -$826K
AMGN icon
16
Amgen
AMGN
$209B
$990K 1.94%
5,805
-4,119
-42% -$756K
BIIB icon
17
Biogen
BIIB
$30.9B
$963K 1.89%
3,517
-2,276
-39% -$706K
INCY icon
18
Incyte
INCY
$25.8B
$940K 1.84%
11,278
-7,040
-38% -$635K
REGN icon
19
Regeneron Pharmaceuticals
REGN
$72.9B
$903K 1.77%
2,622
-1,454
-36% -$506K
BMRN icon
20
BioMarin Pharmaceuticals
BMRN
$11.9B
$864K 1.69%
10,656
-6,462
-38% -$555K
CELG
21
DELISTED
Celgene Corp
CELG
$849K 1.67%
9,512
-5,028
-35% -$483K
KYNB
22
Kyntra Bio
KYNB
$27.4M
$845K 1.66%
731
+554
+313% +$730K
ACAD icon
23
Acadia Pharmaceuticals
ACAD
$4.51B
$825K 1.62%
36,733
+29,853
+434% +$827K
LOXO
24
DELISTED
Loxo Oncology, Inc
LOXO
$796K 1.56%
6,900
-6,900
-50% -$734K
CLVS
25
DELISTED
Clovis Oncology, Inc.
CLVS
$686K 1.35%
13,000
-2,000
-13% -$117K
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q1 2018 Portfolio in Review

As of Q1 2018, Opus Point Partners Management held 66 positions worth $51M, down 56% from $116M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opus Point Partners Management withdrew a net $66.3M in Q1 2018, closing 15 positions and reducing 32 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $5.51M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 66% a quarter earlier, followed by Real Estate.

Against the trend, Opus Point Partners Management opened a new position in bluebird bio worth $226K.

  • Opus Point Partners Management's largest Q1 2018 buy was bluebird bio: 102 shares worth $226K.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q1 2018, an estimated $3.42M increase.
  • Opus Point Partners Management's biggest Q1 2018 reduction was Nektar Therapeutics, cutting an estimated $5.9M.
  • Opus Point Partners Management fully exited Bristol-Myers Squibb in Q1 2018, selling an estimated $5.51M.
  • Opus Point Partners Management's ten largest holdings make up 56% of its $51M portfolio in Q1 2018.
  • Opus Point Partners Management opened 2 new positions and closed 15 in Q1 2018.
  • Opus Point Partners Management's portfolio value fell 56% quarter-over-quarter to $51M.

Based on Opus Point Partners Management's 13F filing for Q1 2018, filed 15 May 2018.